Menopause and cardiovascular disease

Journal of Psychosomatic Obstetrics and Gynaecology

Volumn 18, Issue 2, 1997, Pages 113-120

  Van Der Graaf, Y ^a   De Kleijn, M J J ^a   Van Der Schouw, Y T ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cardiovascular disease; Hormone replacement therapy; Menopause; Stroke

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; CHOLESTEROL; ESTROGEN; FIBRINOGEN; GESTAGEN; LIPOPROTEIN; TRIACYLGLYCEROL;

ANTHROPOMETRIC PARAMETERS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CORONARY RISK; EARLY MENOPAUSE; ESTROGEN THERAPY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MENOPAUSAL SYNDROME; MENOPAUSE; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030738983     PISSN: 0167482X     EISSN: None     Source Type: Journal    
DOI: 10.3109/01674829709085577     Document Type: Conference Paper

References (49)

1. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and the risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85: 447-52.
2. Gordon T, Kannel WB, H Ljortland MC, McNamara PM. Menopause and coronary heart disease: the Framingham study. Ann Intern Med 1978;89: 151-61.
3. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-10.
4. Parrish HM, Carr CA, Hall DG, King TM. Time intervals from castration in premenopausal women to development of excessive coronary atherosclerosis. Am J Obstet Gynecol 1967;99:155-62.
5. Robinson RW, Higano N, Cohen WD. Increased incidence of coronary heart disease in women castrated prior to the menopause. Arch Intern Med 1959; 104:908-13.
6. McGill HC Jr. Sex steroid hormone receptors in the cardiovascular system. Postgrad Med 1989;64-8.
7. Ylikorkala O, Kuusi T, Tikkanen MJ, Vlinikka L. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins. J Clin Endocrinol Metab 1987;65: 1238-42.
8. Nederlandse Hartstichting. Hart- en vaatziekten in Nederland. Den Haag 1995.
9. Tracy RE. Sex difference in coronary disease: two opposing views. J Chron Dis 1966;19:1245-51.
10. Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JAE, Rosner B, Hunter DJ, Hennekens CH, Speizer FE. Smoking cessation in relation to total mortality rates in women; a prospective cohort study. Ann Intern Med 1993;119:992-1000.
11. Verschuren WMM, Achterberg PW, Bijnen FCH, Bueno de Mesquita HB, Feskens EJM, van Leer EM, Peeters PHM, Seidell JC, Smit HA, Verkleij H. Populatie attributieve risico's. In: Ruwaard D, Kramers PGN (eds). Volksgezondheid toekomst verkenning RIVM SdUUitgeverij Plantijnstraat, Den Haag, 1993.
12. Dawber TR. The Framingham study. The epidemiology of atherosclerotic disease. Harvard University Press, Massachusetts, USA. 1980.
13. Weiss NS. Relationship of menopause to serum cholesterol and arterial blood pressure. The United States health examination survey of adults. Am J Epidemiol 1972;96:237-41.
14. Lindquist O, Bengtsson C. Serum lipids, arterial blood pressure and body weight in relation to the menopause: results from a population study of women in Göteborg. Sweden. Scand J Clin Lab Invest 1980;40:629-36.
15. Bonithon-Kopp C, Scarabin PY, Darne B, Malmejac A, Guize L. Menopause-related changes in lipoproteins and some other cardiovascular risk factors. Int J Epidemiol 1990;19:42-8.
16. Berestijn van ECH, Riedstra M, van der Wel A, Schouten EG, Burema J, Kok FJ. Habitual dietary calcium intake and blood pressure change around the menopause: a longitudinal study. Int J Epidemiol 1992;21:683-9.
17. Hjortland MC, McNamara PM, Kannel WB. some atherogenic concomitants of menopause: the Framingham study. Am J Epidemiol 1976;103: 304-11.
18. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321:641-6.
19. Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y. Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Br J Haematol 1990;74:77-81.
20. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85:447-52.
21. Bush TL, Cowan L, Heiss G, Chambliss L, Wallace R. Ovarian function and lipid/lipoprotein levels. Results from the lipid research clinics program (abstract). Am J Epidemiol 1984;120:489.
22. Campos H, McNamara JR, Wilson PWF, Ordovas JM, Schaefcr EJ. Differences in low density lipoprotein subfractions and apolipoprotein in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1988;67:30-5.
23. Witteman JCM, Grobbee DE, Kok FJ, Hofman A, Valkenburg HA. Increased risk of atherosclerosis in women after the menopause. Br Med J 1989;298: 642-4.
24. Pansini F, Bonaccorsi G, Calisesi M, Campobasso C, Franze GP, Gilli G, Locorotondo G, Mallica G. Influence of spontaneous and surgical menopause on atherogenic metabolic risk of atherosclerosis in women after the menopause. Maturitas 1993;17:181-90.
25. Wu ZY, Wu XK, Zhang YW. Relationship of menopausal status and sex hormones to serum lipids and blood pressure. Int J Epidemiol 1990;19:297-302.
26. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990;12:321-31.
27. Barrett-Connor EL. Obesity, atherosclerosis, and coronary artery disease. Ann Intern Med 1985; 103:1010-19.
28. Ostlund RE Jr, Staten M, Kohrt WM, Schulz J, Malley M. The ratio of waist-to-hip circumference, plasma insulin level, and glucose intolerance as independent predictors of the HDL cholesterol level in older adults. N Engl J Med 1990;322:229-34.
29. Edwards DAW Differences in the distribution of subcutaneous fat with sex and maturity. Clin Sci 1951;10:305-15.
30. Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body-fat distribution. Am J Clin Nutr 1992;55:950-4.
31. Barrett-Connor EL, Bush TL. Oestrogen and coronary heart disease in women. J Am Med Assoc 1991;265:1861-7.
32. Colditz GA, Willett WC, Stampfer MJ, Posner B, Speizer FE, Hennekens CH. A prospective study of age at menarche, parity, age at first birth and coronary heart disease in women. Am J Epidemiol 1987; 126:861-70.
33. Robinson RW, Higano N, Cohen WD. Increased incidence of coronary heart disease in women castrated prior to menopause. Arch Intern Med 1959; 104:908-13.
34. Schouw van der YT, van der Graaf Y, Steyerberg EW, Eijkemans MJC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996; 347:714-8.
35. Stampfer MJ, Colditz GA. Oestrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
36. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981;1:858-60.
37. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: The Framingham Study. N Engl J Med 1985;313:1038-43.
38. Grodstein F, Stampfer MJ, Manson J, Colditz GA, Willen WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335:453-61.
39. Miller VT, Muesing RA, LaRosa JC, Story DB, Philips EA, Stillman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-1. Obstet Gynecol 1991;77: 235-40.
40. Burch JC, Byrd BF Jr, Vaughn WK. The effects of long-term estrogen on hysterectomized women. Am J Obstet Gynecol 1974;188:778-82.
41. MacMahon B. Cardiovascular disease and noncontraceptive oestrogen therapy. In: Oliver MF, Ed. Coronary Heart Disease in Young Women. New York: Churchill Livingstone, 1978:197-207.
42. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynecol 1987;94:620-35.
43. Vandenbroucke JP. How much of the cardioprotective effect of postmenopausal ocstrogens is real? (Editorial) Epidemiology 1995;6:207-8.
44. Posthuma WFM, Westendorp RGJ, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? Br Med J 1994;308:1268-9.
45. Hemminki E, Sihvo S. A review of postmenopausal hormone therapy recommendations potential for selection bias. Obstet Gynecol 1993;82:1021-8.
46. Sturgeon SR, Schairer C, Brinton LA, Pearson T, Hoover RN. Evidence of a healthy oestrogen user survivor effect. Epidemiology 1995;6:227-31.
47. Grady D, Rubin SM, Petitti DB, Fox CF, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 1992;117:1016-37.
48. The Writing group of the REPI trial. Rationale, design, and conduct of the PEPI trial. Controlled Clinical trials 1995;16:3S-19S.
49. The Writing group of the PEPI trial. Effects of oestrogen or oestrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal oestrogen/progestin interventions (PEPI) trial. J Am Med Assoc 1995;273:199-208.